PDE10 Program

FORUM Pharmaceuticals is developing FRM-6308, an investigational phosphodiesterase (PDE) inhibitor that is novel, highly potent, and highly selective. To date, FRM-6308 has demonstrated efficacy in preclinical schizophrenia animal models that, in the past, have been predictive of clinical benefit in patients. This activity may be potentially useful to treat positive, negative, and cognitive symptoms in patients with acute and chronic schizophrenia and represents a completely new treatment approach.

FORUM Pharmaceuticals is currently conducting Phase 1b studies of FRM-6308.